CD30

TNFRSF8
Identifiers
AliasesTNFRSF8, CD30, D1S166E, Ki-1, tumor necrosis factor receptor superfamily member 8, TNF receptor superfamily member 8
External IDsOMIM: 153243; MGI: 99908; GeneCards: TNFRSF8
Available structures
PDBOrtholog search: PDBe RCSB
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez

943

21941

Ensembl

ENSG00000120949

ENSMUSG00000028602

UniProt

P28908

Q60846

RefSeq (mRNA)

NM_001243
NM_001281430
NM_152942

NM_009401

RefSeq (protein)

NP_001234
NP_001268359

NP_033427

Location (UCSC)Chr 1: 12.06 – 12.14 MbChr 4: 144.99 – 145.04 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

TNF receptor superfamily member 8, also known as CD30, is a cell membrane protein of the tumor necrosis factor receptor family encoded by the TNFRSF8 gene. It is a tumor marker for Hodgkin lymphoma and anaplastic large cell lymphoma.

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.[citation needed] Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on Reed–Sternberg cells typical for Hodgkin's lymphoma.

Cancer treatment

CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in:

  1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
  2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
  3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen
  4. Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy
  5. Various types of CD30-positive T cell lymphomas

Brentuximab vedotin is also currently being studied in and recommended for treating:

  1. Various types of CD30-positive B cell lymphomas
  2. CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell lymphoma, nasal type

Interactions

CD30 has been shown to interact with TRAF5, and TRAF2.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000120949 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000028602 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. 1 2 "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily member 8". National Library of Medicine, National Center for Biotechnology Information. 22 September 2022. Retrieved 6 November 2022.
  6. 1 2 3 Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, et al. (January 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry. 272 (4): 2042–2045. doi:10.1074/jbc.272.4.2042. PMID 8999898.
  7. 1 2 Duckett CS, Thompson CB (November 1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes & Development. 11 (21): 2810–2821. doi:10.1101/gad.11.21.2810. PMC 316646. PMID 9353251.
  8. ↑ Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese). 34 (11): 711–5. PMID 16536313.
  9. ↑ Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology. 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.
  10. ↑ Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research. 19 (1): 22–7. doi:10.1158/1078-0432.CCR-12-0290. PMID 23155186.
  11. ↑ "FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma". FDA.gov. Archived from the original on November 14, 2017. Retrieved March 2, 2018.
  12. ↑ "FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot". FDA.gov. 24 March 2020. Archived from the original on December 15, 2019. Retrieved December 13, 2023.
  13. ↑ Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F (January 2017). "Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review". Critical Reviews in Oncology/Hematology. 109: 42–50. doi:10.1016/j.critrevonc.2016.11.009. PMC 5218629. PMID 28010897.
  14. ↑ Hu B, Oki Y (2018). "Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma". Frontiers in Oncology. 8: 139. doi:10.3389/fonc.2018.00139. PMC 5937056. PMID 29761078.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.